FY2025 Earnings Forecast for SABS Issued By Chardan Capital

SAB Biotherapeutics, Inc. (NASDAQ:SABS) – Stock analysts at Chardan Capital raised their FY2025 earnings per share (EPS) estimates for SAB Biotherapeutics in a research note issued to investors on Tuesday, April 1st. Chardan Capital analyst K. Nakae now anticipates that the company will post earnings of ($2.65) per share for the year, up from their prior estimate of ($3.64). Chardan Capital currently has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for SAB Biotherapeutics’ current full-year earnings is ($3.69) per share. Chardan Capital also issued estimates for SAB Biotherapeutics’ FY2025 earnings at ($2.65) EPS.

SAB Biotherapeutics (NASDAQ:SABS) last posted its earnings results on Friday, March 28th. The company reported ($1.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.07). SAB Biotherapeutics had a negative net margin of 1,450.14% and a negative return on equity of 94.37%. The business had revenue of $0.05 million during the quarter, compared to analysts’ expectations of $0.12 million.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $6.00 price objective on shares of SAB Biotherapeutics in a research note on Tuesday. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, SAB Biotherapeutics has an average rating of “Buy” and an average target price of $11.40.

SAB Biotherapeutics Trading Down 4.2 %

Shares of NASDAQ:SABS opened at $1.13 on Friday. The company has a 50-day moving average price of $1.78 and a 200 day moving average price of $2.78. The company has a quick ratio of 3.69, a current ratio of 3.69 and a debt-to-equity ratio of 0.09. SAB Biotherapeutics has a 12 month low of $1.00 and a 12 month high of $5.01.

Hedge Funds Weigh In On SAB Biotherapeutics

Several hedge funds have recently bought and sold shares of the business. Northern Trust Corp purchased a new stake in shares of SAB Biotherapeutics during the fourth quarter valued at $43,000. Geode Capital Management LLC boosted its position in SAB Biotherapeutics by 18.8% in the 4th quarter. Geode Capital Management LLC now owns 80,234 shares of the company’s stock valued at $307,000 after buying an additional 12,692 shares during the period. Kovitz Investment Group Partners LLC bought a new position in SAB Biotherapeutics in the 3rd quarter worth about $52,000. Diadema Partners LP bought a new stake in shares of SAB Biotherapeutics during the fourth quarter valued at approximately $114,000. Finally, HB Wealth Management LLC boosted its holdings in shares of SAB Biotherapeutics by 118.6% in the fourth quarter. HB Wealth Management LLC now owns 237,400 shares of the company’s stock valued at $982,000 after purchasing an additional 128,800 shares during the period. Institutional investors own 7.82% of the company’s stock.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.